John Libbey Eurotext

European Journal of Dermatology


Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment Volume 28, numéro 2, March-April 2018


  • Figure 1
1 Division of Dermatology, Mito Kyodo General Hospital
2 Department of Diabetes and Endocrinology, Mito Kyodo General Hospital
3 Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Localized bullous pemphigoid (LBP) is characterized by localized subepithelial tense blisters and erythematous lesions. Although dipeptidyl peptidase-4 (DPP-4) inhibitors can increase the risk of developing bullous pemphigoid (BP) [1], there is no report on the association between LBP and DPP-4 inhibitors. We report a patient with DPP-4 inhibitor-associated LBP, who presented with a single recurrent blister on the extensor surface of his right arm.A 67-year-old man had been treated for type 2 diabetes [...]